Anticancer Ruthenium Complexes with HDAC Isoform Selectivity

The histone deacetylase (HDAC) enzymes have emerged as an important class of molecular targets in cancer therapy, with five inhibitors in clinical use. Recently, it has been shown that a lack of selectivity between the 11 Zn-dependent HDAC isoforms may lead to unwanted side-effects. In this paper, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cross, Jasmine M., Blower, Tim R., Kingdon, Alexander D. H., Pal, Robert, Picton, David M., Walton, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287671/
https://www.ncbi.nlm.nih.gov/pubmed/32455529
http://dx.doi.org/10.3390/molecules25102383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287671/
https://www.ncbi.nlm.nih.gov/pubmed/32455529
http://dx.doi.org/10.3390/molecules25102383

Ejemplares similares